HCPLive® peer-to-peer panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's healthcare professionals.
Nephrology experts discuss the persistent clinical burden of IgA nephropathy, the 2025 KDIGO framework, mechanisms and trial data for newly approved B-cell-targeted therapies, safety monitoring, and practical strategies for treatment selection, sequencing, and personalization.
Pulmonary hypertension experts discuss individualizing therapy for pulmonary arterial hypertension (PAH), from guideline-based risk stratification and upfront combination therapy to escalation, switching, and parenteral transitions, with practical guidance on right heart assessment, adherence, emerging therapies, and partnering with community clinicians.
Expert dermatologists examine the evolving role of oral systemic therapies in plaque psoriasis, from PDE4 and TYK2 inhibition to oral IL-23 receptor blockade. The panel reviews head-to-head, long-term, and high-impact site data, safety and monitoring requirements, route-of-administration preferences, and emerging evidence on off-treatment remission and dose de-escalation.
Expert dermatologists examine the burden of hidradenitis suppurativa, including how draining tunnels affect disease severity, quality of life, and treatment response, and discuss how emerging evidence can guide earlier treatment decisions, individualized goals, and long-term outcomes.
Dermatologists review chronic inducible urticaria subtypes, diagnosis, and quality-of-life burden; the limits of trigger avoidance and antihistamines; and the evolving advanced-therapy landscape, including the phase 3 REMIND data and new approval in symptomatic dermographism, safety, guideline positioning, switching strategies, and emerging mast cell–targeted mechanisms.
International experts in gastroenterology, hepatology, rheumatology, and immunology discuss how IgG4-related disease presents across organ systems, how to distinguish it from its mimics, and why B cells drive its biology. They review glucocorticoid-sparing strategies, phase 3 data on B-cell depletion and inhibition, emerging therapies, long-term monitoring, and new international guidelines.
Gastroenterology experts discuss eosinophilic esophagitis as a chronic, progressive disease, covering earlier recognition, endoscopic and biopsy best practices, individualized treatment selection with topical steroids and biologics, new long-term and phase 4 data, strategies for access and persistence, pediatric transition, and emerging therapeutic targets for sustained disease control.
A pediatric endocrinologist, a complex care pediatrician, and a clinical geneticist trace achondroplasia from its FGFR3 origins through diagnosis and skeletal and airway complications to the growing menu of CNP-pathway and investigational therapies, closing with guidance on monitoring, care coordination, and the patient advocacy organizations that support families long-term.
Advanced practice providers discuss the evolving recognition, diagnosis, and management of eosinophilic esophagitis, from identifying subtle symptoms and atopic comorbidities to selecting individualized therapy, monitoring long-term disease control, and navigating access barriers, with a look at emerging treatments expanding the field.
In this HCPLive Peer Exchange, four pulmonology experts specializing in bronchiectasis and non-tuberculous mycobacterial disease discuss the condition's evolving epidemiology, diagnostic workup, and multidisciplinary care model. The panel reviews the new CHEST guidelines, emerging DPP1 inhibitor therapy, and practical strategies for integrating airway clearance, inhaled antibiotics, and anti-inflammatory treatment into everyday bronchiectasis management.
Expert pulmonologists and an allergist examine the evolving understanding of severe asthma and unified airway disease, including epithelial barrier dysfunction, epithelium-driven inflammation, and the upstream role of TSLP across diverse phenotypes. The panel reviews biomarkers, biologic selection, remission, and how integrated assessment and individualized strategies optimize outcomes in coexisting upper airway disease.
Expert nephrologists examine the rapidly evolving landscape of IgA nephropathy, from 2025 KDIGO guideline updates and the limits of proteinuria to earlier diagnosis, biopsy interpretation, and the mechanisms and trial data behind newly approved drug classes, offering candid, practical guidance on sequencing targeted therapies and redefining treatment success.
Experts examine the burden of psoriatic disease across skin and joints, the biologic pathways driving it, and head-to-head data comparing IL-17 and IL-23 inhibition. The panel makes the case for on-treatment remission as an achievable, patient-defined goal in moderate to severe psoriasis and psoriatic arthritis.
Hypercortisolism is increasingly recognized as an underdiagnosed contributor to resistant hypertension, cardiovascular disease, and broader cardiometabolic dysfunction. In this Peer Exchange, a panel of expert cardiologists discusses the evolving evidence linking cortisol excess to difficult-to-control hypertension, explores practical approaches to patient identification and screening, and reviews the implications of recent studies, including MOMENTUM and CATALYST. The faculty examine emerging treatment strategies, the role of multidisciplinary care, and opportunities to improve long-term outcomes through earlier recognition and targeted management of hypercortisolism. Throughout the discussion, they highlight how increasing awareness of cortisol excess may help clinicians uncover a potentially reversible driver of cardiovascular risk in everyday practice.
This peer exchange brings together expert endocrinologists to discuss the recognition, diagnosis, and management of hypercortisolism across its evolving disease spectrum. The panel explores the links between cortisol excess, cardiometabolic dysfunction, type 2 diabetes, and resistant hypertension, while reviewing practical approaches to screening and confirmatory testing. Faculty also examine current treatment strategies, emerging clinical evidence, and the importance of multidisciplinary care to improve patient outcomes.
In this HCPLive Peer Exchange, Dr. Natalie Cusano moderates a comprehensive discussion with Dr. Sara Lubitz, Dr. Dolores Shoback, Dr. Andrea Ferenczi, and Dr. Azarmindokht Khosravi on hypoparathyroidism, covering its multisystem burden, diagnostic challenges, treatment strategies, and evolving therapeutic landscape.
In this HCPLive Peer Exchange series, expert panelists discuss key updates and clinical insights related to ASCVD. The discussion focuses on updated cardiovascular risk assessment guidelines and LDL cholesterol goals, practical strategies for initiating and escalating lipid-lowering therapy, and the critical role of patient communication, shared decision making, and long-term adherence in closing the persistent gap between guideline-recommended targets and real-world clinical outcomes.
Expert endocrinologists examine growth hormone deficiency across pediatric and adult populations, covering etiology, diagnosis, treatment options including long-acting analogs, real-world registry data, transition-of-care challenges, and strategies for optimizing long-term patient outcomes across the continuum of care.
In this HCP Live Peer Exchange series, expert panelists discuss key updates and clinical insights related to Psoriasis. The discussion focuses on the evolving treatment approaches in psoriasis and how they aim to achieve sustained disease control beyond short-term skin clearance. The panelists evaluated long-term efficacy and safety data to better understand durability of response and the potential for sustained remission in psoriasis. They also explored how to incorporate evidence-based, remission-focused strategies into clinical management and patient communication in everyday practice.
This HCPLive Peer Exchange series provides a comprehensive evaluation of Wilson disease, from its underlying pathophysiology and clinical manifestations to the diagnostic criteria that impact long-term patient quality of life. The panelists analyze the safety and efficacy of current and emerging therapeutic paradigms while offering practical, data-driven strategies to overcome management challenges and improve medication adherence.
In this Peer Exchange, Dr. Vivek Kaul moderates a comprehensive discussion with Jennifer Geremia, PA-C, and Sarah Enslin, PA-C, covering EPI's symptom recognition, high-risk populations, diagnostic testing, PERT therapy, dose optimization, multidisciplinary care coordination, and key recommendations for closing persistent care gaps.
In this HCP Live Peer Exchange series, expert panelists discuss key updates and clinical insights related to Psoriasis. The discussion focuses on the pathophysiology of hypercortisolism, and how it contributes to hypertension and cardiovascular risk. The panelists will review the current and emerging treatment landscape and consider how evolving therapies may influence patient outcomes. Finally, the panelists will discuss practical approaches to cardiovascular management, including interdisciplinary collaboration and referral considerations in the care of patients with hypercortisolism
In this HCPLive Peer Exchange series, expert panelists discuss key updates and clinical insights related to obstructive hypertrophic cardiomyopathy. The discussion focuses on the pathophysiology, symptoms, and diagnostic approaches for obstructive hypertrophic cardiomyopathy (oHCM) to provide a foundation for patient management. It also examines treatment strategies, best practices for optimizing care, and how recent clinical trial data can be applied to improve outcomes in oHCM patients.
In this HCPLive Peer Exchange series, expert panelists discuss key updates and clinical insights related to plaque psoriasis. The discussion focuses on the clinical and practical challenges of managing moderate to severe plaque psoriasis, while evaluating the evolving treatment landscape with a particular emphasis on IL-23 inhibitors and the value of matching adjusted indirect comparisons in evidence-based decision making. The panelists also share best practices for integrating comparative evidence into real world practice to guide treatment selection, support patient centered discussions, and optimize long term outcomes.
In this HCPLive Peer Exchange series, expert panelists discuss the critical link between chronic kidney disease (CKD) and cardiovascular risk, emphasizing the necessity of early diagnostic testing. The multidisciplinary panel—comprising a cardiologist, a family physician, and a cardiovascular clinical pharmacist—explores how the integrated cardio-kidney-metabolic (CKM) framework can be used to improve patient outcomes
In thisHCPLive Peer Exchange series, expert panelists discuss key updates and clinical insights related to primary biliary cholangitis. The discussion focuses on new second-line treatment data and improving fatigue/pruritus symptoms.
In this HCPLive Peer Exchange series, expert panelists discuss key updates and clinical insights related to hypoparathyroidism. The discussion focuses on the etiology, diagnosis, long-term complications, and novel treatment approaches in the management of hypoparathyroidism.
This program brings together leading nephrologists to discuss the evolving landscape of IgA nephropathy, highlighting advances in understanding disease mechanisms and the emergence of targeted therapies. The panel reviews key clinical data, explores the role of novel treatment strategies such as B-cell modulation, and examines how these innovations may reshape modern patient management.
Experts discuss Giant Cell Arteritis presentation, epidemiology and pathophysiology, tackling diagnostic hurdles and long‑term management. Experts also reviews current and emerging therapies that can improve outcomes while lowering risks.
Panelists explore challenges in diagnosing and managing Sjogren’s Disease, evaluate emerging therapies, and share key considerations for integrating novel treatments into clinical practice.
